Abstract:Background In resectable oesophageal squamous cell carcinoma (ESCC), the eff i cacy of camrelizumab combined with chemotherapy and apatinib followed by minimally invasive oesophagectomy is not clear. We aimed to fi ll this knowledge gap. Methods This investigator-initiated, single-arm, prospective, phase 2 trial was performed at the Second Aff i liated Hospital of Zhejiang University, China. Patients (aged 18 - 75 years) who were histologically or cytologically diagnosed with ESCC were deemed suitable to participate in this trial. Patients received 2 - 3 cycles of neoadjuvant therapy with camrelizumab, nedaplatin, albumin paclitaxel, and apatinib; each cycle was repeated every 14 days. Surgery occurred 4 - 6 weeks after the last neoadjuvant treatment cycle. The primary outcome was the pathological complete response (PCR) rate of the tumour and lymph nodes. The changes in the peripheral blood immunopro fi le among patients without PCR (ie, non-PCR [NPCR]) and with PCR were assessed by mass cytometry. This study was registered with ClinicalTrials.gov, NCT04666090. Findings 42 patients were enrolled between November 23, 2020 and December 31, 2022. The disease control rate was 100.0% (95% CI, 91.6 - 100%), and the objective response rate was 83.3% (95% CI, 68.6 - 93.0%). Six (14.3%) patients experienced grade 3 adverse events. The most common were white blood cell count decrease (31.0%), alopecia (81.0%), asthenia (38.1%), and reactive cutaneous capillary endothelial proliferation (35.7%). 41 patients received minimally invasive oesophagectomy; all 41patients achieved R0 resection, and 18 (43.9%, 95% CI, 28.5 - 60.3%) patients achieved PCR. The median follow-up was 23 months and the 2-year survival rate was 85.9%. T-cell subsets in both the PCR and NPCR groups exhibited consistency in response to neoadjuvant therapy. In contrast, some of natural killer (NK) cells (NK-C03, NK-C11), B cells (B -C06) and monocytes (M -C05), exhibited signi fi cant differences between the PCR and NPCR groups before neoadjuvant therapy. M -C06 had a signi fi cant difference in the PCR group and NPCR group after neoadjuvant therapy. NK-C12 and B -C15 showed signi fi cant differences both before and after neoadjuvant therapy. Interpretation The application of camrelizumab, chemotherapy and apatinib in the neoadjuvant setting for locally advanced ESCC has shown promising antitumour activity and an acceptable safety pro fi le in this single-arm study. In the neoadjuvant setting, NK cell, B cell, and monocyte subsets exhibited greater predictive power for immunotherapy responsiveness than T-cell subsets. Longer follow-up to assess survival outcomes and a phase 3 randomised trial are needed to further evaluate the proposed treatment.

Treatment of cavitated non-small cell lung cancer presenting as "Halloween pumpkin" following the consecutive NEOADAURA and ADAURA2 strategy: A case report

Osimertinib As Neoadjuvant Therapy in Patients with EGFR-mutant Resectable Stage II-IIIB Lung Adenocarcinoma (NEOS): A Multicenter, Single-Arm, Open-Label Phase 2b Trial.

Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).

Radical resection in a patient with stage IIIA non-small cell lung cancer with the EGFR exon 19 deletion mutation after neoadjuvant targeted therapy with osimertinib: a case report

OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib As Adjuvant Therapy for Resected EGFR Mutated NSCLC

Adjuvant Osimertinib in Patients with Stage IB to IIIA EGFR Mutation-Positive NSCLC after Complete Tumor Resection: ADAURA China Subgroup Analysis

Camrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Oesophageal Squamous Cell Carcinoma: a Single-Arm Phase 2 Trial

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series

OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib As Adjuvant Therapy in Patients with Resected EGFR Mutated (egfrm) NSCLC

Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases

A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study

85P Adjuvant osimertinib in patients (pts) with stage IB–IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis

Triple Administration of Osimertinib Followed by Chemotherapy for Advanced Lung Adenocarcinoma: A Case Report

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

A Plain Language Summary of Results from the ADAURA Study: Osimertinib after Surgery for Patients Who Have Early-Stage EGFR-mutated Non-Small Cell Lung Cancer.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial